Start
•
Completion

Ketamine Plus Lithium in Treatment-Resistant Depression

CompletedRegisteredCTG

Randomized, double-blind, placebo-controlled Phase II study (n=34) testing repeated ketamine infusions over 1 week with nightly lithium (600–1200 mg) versus placebo pills in treatment-resistant major depressive disorder to assess efficacy and relapse prevention.

Details

Randomized, double-blind, parallel-group Phase II trial in adults (21–65) with treatment-resistant major depressive disorder comparing ketamine infusions plus lithium versus ketamine plus placebo; target enrollment 34.

Primary aim is to test whether adjunctive lithium sustains ketamine's rapid antidepressant effects; secondary aims include safety, tolerability, and effects on brain function.

Topics:Treatment-Resistant Depression (TRD)

Registry

Registry linkNCT01880593